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The neuregulin1/ErbB system plays an important role in Schwann cell behavior both in normal and pathological conditions. Upon
investigation of the expression of the neuregulin1/ErbB system in vitro, we explored the possibility to manipulate the system in
order to increase the migration of Schwann cells, that play a fundamental role in the peripheral nerve regeneration. Comparison
of primary cells and stable cell lines shows that both primary olfactory bulb ensheathing cells and a corresponding cell line express
ErbB1-ErbB2 and neuregulin1, and that both primary Schwann cells and a corresponding cell line express ErbB2-ErbB3, while only
primary Schwann cells express neuregulin1. To interfere with the neuregulin1/ErbB system, the soluble extracellular domain of the
neuregulin1 receptor ErbB4 (ecto-ErbB4) was expressed in vitro in the neuregulin1 expressing cell line, and an unexpected increase
in cell motility was observed. In vitro experiments suggest that the back signaling mediated by the transmembrane neuregulin1
plays a role in the migratory activity induced by ecto-ErbB4. These results indicate that ecto-ErbB4 could be used in vivo as a tool
to manipulate the neuregulin1/ErbB system.
1. Introduction
The neuregulin1/ErbB system plays an important role in
Schwann cell (SC) behavior both in normal and pathological
conditions [1] and the possibility to manipulate it gives new
perspectives to improve posttraumatic nerve regeneration
[2–4].
The ErbB receptor family consists of four tyrosine kinase
receptors: epidermal growth factor receptor (EGFR, also
called ErbB1 or HER1), ErbB2, ErbB3, and ErbB4 [5]. ErbB
receptors bind several structurally related growth factors.
Among them, neuregulin1 (NRG1) is the most characterized
and studied in the peripheral nervous system (PNS) for its
role in axon-glial signaling and SC activity. The NRG1 gene
codes for more than 20 different isoforms [1, 6–8] which
differ because of alternatively spliced exons. Actually, soluble
and transmembrane isoforms were described that differ in
the presence of N-terminal domains and their signaling
mode: soluble isoforms (types I and II) are mainly released
by glial cells and signal in a paracrine/autocrine manner;
transmembrane isoforms (type III) are mainly expressed
by axons and signal in a juxtacrine manner [8]. NRG1 are
further classified as alpha and beta isoforms, according to the
characteristics of their EGF-like domain.
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It has been shown that transmembrane ligand-receptor
interactions may lead to a process of back-signaling, which is
mediated by the action of a 𝛾-secretase enzyme which causes
the release of a cytoplasmic fragment able to translocate into
the nucleus [9, 10].
In order to better study the role of the NRG1/ErbB system
in the peripheral nerve, four different in vitro models were
analyzed: primary rat SC harvested from sciatic nerve, a SC
line (RT4-D6P2T) [11], primary glial cells of the olfactory
nerve, known as olfactory ensheathing cells (OEC), and
a neonatal olfactory bulb ensheathing cell line (NOBEC)
[12]. In vitro experiments were carried out to address these
questions.
Are NRG1 and ErbB receptor expressed in these
four cellular models? What are the in vitro effects of
manipulating theNRG1/ErbB systemby expression of
the soluble extracellular domain of theNRG1 receptor
ErbB4 (ecto-ErbB4) in glial cells?
2. Materials and Methods
2.1. In Vitro Assays
2.1.1. Cultures of NOBEC, RT4-D6P2T, and COS7. Neonatal
olfactory bulb ensheathing cells (NOBEC) line, derived from
primary cells dissociated from neonatal rat olfactory bulb
and immortalized by retroviral transduction of SV40 large T
antigen [12], was kindly provided by Dr. Jacobberger (Com-
prehensive Cancer Center, Case Western Reserve University,
10900 Euclid Avenue, Cleveland, OH 4106-4944, USA). Rat
RT4-D6P2T [11] and COS7 were provided by the American
Type Culture Collection (ATCC). Cell lines were grown as
monolayer at 37∘C in a humidified atmosphere of 5%CO
2
/air,
in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen,
UK) supplemented with 100U/mL penicillin, 100 𝜇g/mL
streptomycin, 1mMsodiumpyruvate, 2mM l-glutamine, and
10% heat-inactivated foetal bovine serum (FBS; Invitrogen).
Recombinant NRG1𝛽1 has been produced in the laboratory
as a His-tag fusion protein in E. coli [13].
2.1.2. Cultures of Primary Schwann Cells (SC). To harvest
Schwann cells (SC), rat sciatic nerves were exposed, removed,
and kept in DMEM plus glutamax (Invitrogen, UK) con-
taining 100U/mL penicillin and 100 𝜇g/mL streptomycin.
Nerves were then dissected in trunks, desheathed, and finally
chopped in 1mm segments. The segments were then plated
in a Petri dish in SC growth medium (DMEM plus glutamax
containing 100U/mL penicillin, 100 𝜇g/mL streptomycin,
14 𝜇Mforskolin, and 100 ng/mLNRG1𝛽1, R&DSystems, UK).
Cells were incubated for 2 weeks at 37∘C with fresh medium
added approximately every 72 h. After these 2 weeks medium
was aspirated and 0.125% (w/v) collagenase type IV and
117U/mg dispase were added to the Petri dish. After 24 hours
(h) incubation, cell suspension was filtered through a 70mm
cell strainer (Falcon; BD Biosciences Discovery Labware,
Bedford, MA) and centrifuged at 100×g for 5min to obtain
the cell pellet. Finally, the cell pellet was resuspended in SC
growth medium, seeded into a Petri dish pre-coated with
poly-D-lysine (Sigma, St Louis, MO, USA), and incubated
in the same conditions. The following day, the medium was
changed and cells were left to proliferate. When confluent,
SC were purified by an antibody complement method to
eradicate the remaining fibroblasts [14–16].
2.1.3. Cultures of Primary Olfactory Ensheathing Cells (OEC).
OEC were isolated from 2-day-old rat pups (P2) olfactory
bulbs using an already described method [17]. Ten neonatal
rats were used to produce each batch of OEC. Initial steps
involved peeling away the olfactory nerve layer from the rest
of the bulb and digesting the tissue in MEM-H containing
0.03% collagenase and 0.25% trypsin for 15min at 37∘C. This
step was repeated twice with a fresh solution. Trypsinization
was stopped by adding 10% foetal calf serum (FCS)-DMEM.
The digested tissue was mechanically dissociated by tritura-
tion and filtrated through a 80𝜇m nylon mesh followed by
centrifugation at 500×g for 10min. Cells were resuspended
and plated in flasks, fed with fresh 10% FCS-DMEM, and-
supplemented with 2mM L-glutamine, 50U/mL penicillin,
and 50 𝜇g/mL streptomycin. 24 h after initial plating, 10𝜇M
antimitotic agent cytosine arabinoside was added to reduce
the number of dividing fibroblasts. OEC cultures were further
processed by passing cells from one flask to another.This step
reduces contaminating cells because they adheremore readily
to plastic than OEC. In the last passage OEC were plated on
25 cm2 flasks and cultured in 10% FCS-DMEM supplemented
with bovine pituitary extract. OEC purity was verified using
immunocytochemistry with p75 and S-100. The percentage
of S-100/p75 positive cells in the cultures was ∼85–90% (data
not shown). Cells were incubated at 37∘C in 10% FCS-DMEM
and the medium was changed twice a week.
2.1.4. GDNF Stimulation Assay. Purified primary OEC and
NOBEC were plated on 14mm diameter poly-L-lysine (PLL,
10 𝜇g/mL, Sigma) coated glass coverslips at a final density
of 3 × 103 cells/coverslip and grown both in 10% FCS-
DMEM and in serum-free DMEM. Cells were cultured with
the addition of Glial Derived Neurotrophic Factor (GDNF,
1 ng/mL, Chemicon) for eight days, changing the medium
twice. Control cultures received medium with no addition
of trophic factor (CTR). Then, cells were processed by
immunocytochemical procedures and total RNA extraction.
2.1.5. Immunocytochemistry. OEC and NOBEC were fixed
in 0.1M phosphate buffer pH 7.4 (PBS) containing 4%
paraformaldehyde (PAF) for 30minutes (min). Afterwashing
in PBS cells were treated with PBS containing 5% normal goat
serum (NGS), 0.1% Triton X-100 at room temperature (RT)
for 15min.OEC andNOBECwere incubated overnight at 4∘C
with the following primary antibodies: anti-S-100 (mouse,
working dilution/w.d. 1 : 100; Sigma Aldrich), antinestin (rab-
bit, w.d. 1 : 100; Immunological Science), and antivimentin
(mouse, w.d. 1 : 50;Dako). Afterwashing, cells were incubated
for 45min at RTwith the correspondent anti-mouse and anti-
rabbit fluorescent secondary antibodies to visualize primary
antibodies. The immunostained coverslips were analyzed on
a Zeiss fluorescence microscope and images were captured
with an Axiovision Imaging System. No staining of cells
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Table 1: Primers used for quantitative real time-PCR reaction.
GENE Forward primer (5󸀠-3󸀠) Reverse primer (3󸀠-5󸀠) Sequenceaccession number AMPLICON
ErbB1 CACCACGTACCAGATGGATG CGTAGTTTCTGGGGCATTTC U52529 85 bp
ErbB2 CACTTGGAGCTTACCTACGTGCC ACCTGGTTGTGAGCGATGAGC NM 017003 98 bp
ErbB3 TGCTGACCTTTCCTTCCTGCAATGG GAGGTTAGGCAAGGGAAGCACAGAG NM 017218.2 94 bp
NRG1
type I GGCGCAAACACTTCTTCATCCAC AAGTTTTCTCCTTCTCCGCGCAC AF 194993 82 bp
NRG1
type III CCCTGAGGTGAGAACACCCAAGTC TGGTCCCAGTCGTGGATGTTGATG AF 194439 103 bp
NRG1 𝛼 GCGGAGAAGGAGAAAACTTTC TTGCTCCAGTGAATCCAGGTTG RNU-02323 112 bp
NRG1 𝛽 GCGGAGAAGGAGAAAACTTTC AACGATCACCAGTAAACTCATTTGG RNU-02322 116 bp
GFAP GAGGCAGTGGCCACCAGTAACATG GGAAGCAACGTCTGTGAGGTCTGC NM 017009 81 bp
S100 GGGTGACAAGCACAAGCTGAAGAA TTGTCCACCACTTCCTGCTCTTTG NM 013191 102 bp
P75 AGCAGACCCATACGCAGACTG TCTCTACCTCCTCACGCTTGG NM 012610 95 bp
was observed in control incubations in which the primary
antibodies were omitted.
2.1.6. Cell Transfection. For transient transfection of plas-
midic DNA, NOBEC, RT4-D6P2T, and COS7 cells were
transfected with Lipofectamine 2000, according to manufac-
turer’s instructions. Efficient expression of the recombinant
protein was assessed by Western blot analysis.
2.1.7. Cell Migration Assay. Transwell assays were performed
48 h after DNA transfection as previously described [18]. To
inhibit the 𝛾-secretase, cells were pretreated with 100 𝜇M
DAPT (𝛾-secretase inhibitor compound IX, Calbiochem) for
3 days. Since DAPT was diluted with DMSO, the control was
carried out by treating cells with the same volume of this
solvent.
For each Transwell four images were analyzed and the
amount of migrated cells was evaluated as the total area of
migration (in pixel2) was calculated with the Image J software
and expressed as percentage of the total number of migrated
cells for each single experiment. Cells were discriminated by
the pores of the Transwell membrane by applying a threshold
of 300 pixel2. For each experimental condition a technical
triplicate wasmade and each experiment was repeated at least
3 times.
2.1.8. RNA Isolation and cDNA Preparation. Total RNA was
extracted with TRIzol (Invitrogen) according to the manu-
facturer’s instructions, adding 5 𝜇g glycogen as a carrier to
facilitate RNA precipitation. 1 𝜇g total RNA was subjected to
a reverse transcriptase (RT) reaction in 25𝜇L reaction vol-
ume containing 1X RT-Buffer (Fermentas); 0.1 𝜇g/𝜇L bovine
serum albumin (BSA, Sigma); 0.05% Triton X-100; 1mM
dNTPs; 7.5 𝜇M random exanucleotide primers (Fermentas);
1 U/𝜇L RIBOlock (Fermentas); and 200U RevertAid M-
MuLV reverse transcriptase (Fermentas). The reaction was
performed for 10min at 25∘C, 90min at 42∘C, and 10min at
90∘C. Control reactions “RT-” (without the enzyme RT) and
“H
2
O”, without RNA, were carried out.
2.1.9. Quantitative Real-Time PCR (qRT-PCR) Analysis.
Quantitative real-time PCR analysis was performed using
Sybr Green chemistry; data were analyzed by ΔΔCt rela-
tive quantification method normalizing to the housekeep-
ing gene Tata-box Binding Protein (TBP) (forward primer:
5󸀠-TAAGGCTGGAAGGCCTTGTG-3󸀠; reverse primer: 5󸀠-
TCCAGGAAATAATTCTGGCTCATAG-3󸀠). Real-time PCR
reactions were performed using the 7300 real-time PCR
system (Life Technology). Each sample was run in triplicate
on 96-well optical PCR plates (Life Technology). In each well
a PCR reaction was carried out on 5 𝜇L cDNA corresponding
to 20 ng starting RNA (1 𝜇g RNA retrotranscribed in 25 𝜇L,
diluted 1 : 10 in water), Sybr Green PCR Master Mix (Life
Technology) and 300 nMprimers (Life Technology) in a reac-
tion volume of 25 𝜇L. Specific primers designed to amplify
ErbB1, ErbB2, ErbB3, ErbB4, NRG1, p75NGFR, GFAP, and
S100 are listed in Table 1. After an initial denaturation step for
10min at 95∘C, denaturation in the subsequent 40 cycles was
performed for 15 seconds (sec) at 95∘C followed by primer
annealing and elongation at 60∘C for 1min. Relative amount
of mRNA that had been retrotranscripted into cDNA was
calculated by comparative (ΔΔCt) method. In the first step
of the method, the difference between Ct values of target
and housekeeping gene was calculated (ΔCt), whereas in the
second step the difference between the ΔCt values of the
samples and the calibrator was determined (ΔΔCt). For each
gene, the cells with the highest level of expressionwere chosen
as calibrator. The normalized relative quantity (NRQ) was
determined using the formula: NRQ = 2−(ΔΔCt). Results were
expressed as mean + SEM.
2.1.10. Total Protein Extraction and Western Blot Analysis.
Total proteins were extracted by solubilizing cells in boiling
Laemmli buffer (2.5% SDS, 0.125M Tris-HCl pH6.8), fol-
lowed by 3min at 100∘C. Protein concentration was deter-
mined by the BCA method, and equal amounts of proteins
(denaturated at 100∘C in 240mM 2-mercaptoethanol and
18% glycerol) were loaded onto each lane, separated by SDS-
PAGE, transferred to a HybondTM C Extra membrane as
previously described [19]. Primary antibodies used are ErbB1
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(#sc-03), ErbB2 (#sc-284), ErbB3 (#sc-285), ErbB4 (#sc-283),
NRG1 (#sc-347, #sc-348), w.d. 1 : 1000, from Santa Cruz; p-
AKT (#4051), AKT (#9272), p-ERK (#9106), ERK (#9102)
w.d. 1 : 1000, from Cell Signaling; flag (#F7425) w.d. 1 : 10000,
from Sigma; p75-NGFR (#ab52987), w.d. 1 : 2000, from
Abcam; GAPDH (#4300), w.d. 1 : 20000, and from Ambion;
secondary antibodies used are horseradish peroxidase-
linked anti-rabbit (#NA934) and anti-mouse (#NA931) w.d.
1 : 40000, from GE Health.
2.1.11. Nuclear andCytoplasmic Protein Extraction. Cell plates
were washed 3 times with PBS on ice. On each plate, 300𝜇L
of lysis buffer (20mM Tris-HCl pH8.0, 20mM NaCl, 0.5%
NP40, plus an anti-protease cocktail, Roche) was added for
10min at 4∘C.
After lysis, cells and nuclei were collected and centrifuged
for 30min at 3000 rpm at 4∘C, in order to separate the
nuclear and cytoplasmic material; the supernatant, which
contains the cytoplasmic extract, was separated from the
pellet, syringed with a G26 needle and then centrifuged
for 5min at 12000 rpm at 4∘C. Supernatant was collected,
aliquoted, and frozen at −80∘C. The pellet obtained after the
first centrifuge, containing nuclear material, was washed 3
times with lysis buffer and centrifuged, in order to remove
cytoplasmic protein traces. Pellet was resuspended in 30 𝜇L
buffer C (20mM Hepes pH8.0; 1.42mM NaCl, 1.5mM
MgCl
2
, 1.2mM EDTA); then, 30 𝜇L Buffer C containing 50%
glycerol was added, and nuclear proteins were incubated on
ice for 30min. The treatment with this hyperosmotic buffer
causes cell nucleus collapse and nuclear protein spillage. After
incubation, extracts were centrifuged for 90 sec at 12000 rpm
at 4∘C. The supernatant containing nuclear proteins was
collected, centrifuged again, diluted 1 : 3 in 20mMHepes pH
8.0, and stored at −20∘C.
2.2. Construct Preparation
2.2.1. Cloning Strategies for NRG1-ICD-NLS and NRG1-
ICD-ΔNLS Constructs. Because the C terminal cytoplasmic
domain is common to all NRG1 isoforms, the cDNA coding
for NRG1-typeI-𝛽1a (kindly provided by K. Lay, accession
number NM 013956) was used as template to clone the
cytoplasmic domain of NRG1. To allow expression of the
protein, an artificial start codon (ATG, shown in bold in the
primer sequence) was added on the forward primer, inserted
in a Kozac sequence. To obtain an intracellular domain (ICD)
containing the nuclear localization signal (NLS) the following
primers were used:
forward: 5󸀠-TAGCCTGCAGCATGGGCAAAACC
AAGAAACAGCG-3󸀠;
reverse: 5󸀠-ATCGATATCTACAGCAATAGGGTC
TTGGTTAG.
To obtain an intracellular domain (ICD) missing the
nuclear localization signal (ΔNLS), the following primers
were used:
forward: 5󸀠-TAGCCTGCAGCATGGAGCTTCAT
GATCGGCTCC-3󸀠;
reverse: 5󸀠-ATCGATATCTACAGCAATAGGGTC
TTGGTTAG.
Restriction enzymes sequences (underlined) were added
to the primers to facilitate the subcloning (PstI in the forward
primer, EcoRV in the reverse primer).
Amplification reactions were carried out using 0,8 ng
template (NRG1-tipoIII-𝛽1a) and the AmpliTaq Gold
enzyme, following manufacturer’s instructions, in the
Thermal Cycler GeneAmp PCR System 2400 (Perkin Elmer).
The amplification was performed according to the following
protocol: 5min at 94∘C; then 40 cycles: 30 sec at 94∘C, 30 sec
at 60∘C, 90 sec at 72∘C; and 20min at 72∘C. Amplification
products were cloned into the pGEM-T vector, using chemi-
cally competent JM-109 cells (Promega), following manu-
facturer’s instructions. Two clones, corresponding to the
constructs ICD-NLS and ICD-ΔNLS, were completely
sequenced (BMR Genomics Laboratories). Inserts were
recovered by EcoRV and NcoI digestions, sticky ends were
blunted and inserted into pIRESpuro2 (Clontech) previously
cut with NotI, blunted and dephosphorylated.
2.2.2. Cloning Strategies for Ecto-ErbB4-FLAG Construct and
Subcloning into Lentiviral Vector. To obtain a construct to
express the extracellular domain of ErbB4 (ecto-ErbB4) fused
with a FLAG epitope, the ErbB4 extracellular domain, recov-
ered from the pIRES-puro2-ErbB4-JMa-cyt2 construct [18]
by EcoRV and BbsI digestion and blunting, was subcloned
into the EcoRV site of the pCMV-Tag4a vector (Stratagene).
To obtain a lentiviral vector to express ecto-ErbB4-FLAG,
the insert with the FLAG and the following STOP codon
was recovered from pCMV-Tag4c vector by EcoRV and
KpnI digestion and blunting and subcloned into the multiple
cloning sites (mcs) of the lentiviral vector pRRL-CMV-mcs-
WPRE, flanked by the constitutively active CMV promoter
and the woodchuck hepatitis virus posttranscriptional regu-
latory element (WPRE).
2.3. Lentivirus Production and RT4-D6P2T Infection. LV
stocks were generated as previously described [20–22].
Briefly, two 15 cm diameter Petri dishes containing 1.25 × 107
HEK293T seeded in Iscoves modified Dulbecco’s medium
(IMDM) containing 10% FCS, 100U/mL penicillin,
100 𝜇g/mL streptomycin (PS), and Glutamax (Invitrogen)
were prepared. Using branched polyethylenimine (Sigma,
St Louis, MO) a triple transfection with the LV transfer,
packaging (pCMVdeltaR8.74) and envelope (pMD.G.2)
plasmid, was performed (ratio 3 : 2 : 1, total DNA90 𝜇g/plate).
After 14 h, the medium was replaced by IMDM containing
2% FCS, 1% PS and Glutamax. After 24 h, the medium was
harvested, filtered through a 0.22 𝜇m filter, and concentrated
by ultracentrifugation at 20.000 rpm for 2.5 h in a SW32Ti
rotor (Beckman Coulter B, The Netherlands). Viral pellets
were resuspended in PBS pH 7.4 aliquoted and stored at
−80∘C until further use. Serial dilutions (10−2,−3,−4 and
10
−2 to −7 for LV-GFP) of all viral stocks were used to infect
2 × 10
5 HEK293T in IMDM 2% FCS, 1% P/S and Glutamax
seeded in poly-L-lysine (PLL) coated 24-well culture plates.
After 48 h the number of transducing units per mL (TU/mL)
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for the LV-GFP stock was manually quantified by counting
transduction events in the LV-GFP transduced cells using
a fluorescence microscope (10−5,−6,−7) and genomic DNA
(gDNA) of all samples was extracted and measured for viral
integrating events by quantitative PCR (10−2,−3,−4). Briefly,
cells were harvested and gDNAwas extracted (DNeasy Blood
&TissueKit, Qiagen, Venlo, theNetherlands). Viralmediated
transgene integration was measured using primers directed
against the lentiviral WPRE on an ABI 7900HT detection
system (Applied Biosystems) using the SYBR green PCR
kit (Applied Biosystems). WPRE primers sequences were
as follows: 5󸀠-TTCCCGTATGGCTTTCATTT-3󸀠 and 5󸀠-
GAGACAGCAACCAGGATTTA-3󸀠. All expression values
were normalized to that of the reference gene GAPDH.
GAPDH primers were as follows: 5󸀠-TGCACCACCA-
ACTGCTTAGC-3󸀠 and 5󸀠-CGCATGGACTGTGGTCAT-
GA-3󸀠. The ratio between the TU/mL and gDNA WPRE
content of the LV-GFP stock was used to calculate relative
TU/mL titers for all stocks on the basis of their gDNAWPRE
content.
RT4-D6P2T cells seeded at 1 × 103 cells/well in a 96-
well plate were infected using LV-sGFP or a combination
of LV-sGFP and LV-Ecto-ErbB4 FLAG. Cells were infected
three times at a MOI of 100. Confluent cells were harvested,
expanded, and frozen.
Western blot and immunocytochemistry were per-
formed on confluent cells in order to evaluate virus infec-
tion efficiency and sGFP and ecto-ErbB4-FLAG expre-
ssion.
Confluent cells were fixed by incubation with 4% PFA
and permeabilized with 0.2% Triton X-100 diluted in PBS
by 45min incubation at RT. Blocking solution containing
5% FCS diluted in 0.2% Triton X-100 PBS was applied
for 1 h at RT. Monoclonal anti-GFP antibody (1 : 500 in
blocking solution, Abcam) and rabbit anti-FLAG primary
antibody (1 : 500 in blocking solution, Sigma) were incubated
overnight (o/n) at 4∘C. Following 3 washes of 15min each
goat-anti-rabbit IgG (H+L) Cy3 and goat-anti-mouse IgG
(H+L) Alexa 488 secondary antibody (Invitrogen, diluted
1 : 200 in PBS) were incubated for 2 h at RT. Following
3 washes of 15min nuclei were stained using Hoechst
(Sigma) diluted 1 : 1000 in PBS. Fluorescent images were
acquired using an inverted optical microscope (Axiovert 200,
Zeiss). Western blot analysis was performed as described
above.
2.4. Ecto-ErbB4-FLAG Protein Purification
2.4.1. Co-Immunoprecipitation Assay. Ecto-ErbB4-FLAG
protein for coimmunoprecipitation assay was obtained from
conditioned medium of COS7 transiently expressing the
protein. After three days of culture, medium was collected,
centrifuged and 1mL aliquots were incubated with either
100 ng or 200 ng recombinant NRG1𝛽1-Hys protein and
immunoprecipitated as previously described [18] using
an anti-FLAG polyclonal antibody (SIGMA #F7425).
Immunoprecipitated proteins were analyzed by western blot,
using an antibody directed to the hystidine tag.
2.4.2. Ecto-ErbB4-FLAG Protein Production and Purification.
Ecto-ErbB4-FLAG protein for in vitro experiments was
purified from conditioned medium of RT4-D6P2T stably
expressing the protein. After four days of culture in the
presence of serum free medium, medium was collected,
centrifuged, and filtered (0.22𝜇m filter). Target protein was
then purified using ANTI-FLAG M2 affinity gel (SIGMA
#A2220) and eluted by competitive elution using 100 𝜇g/mL
FLAG peptide. Eluted solution was collected in 10 fractions
and aWestern blot was performed to confirm the presence of
target protein. Only positive fractions were frozen in liquid
nitrogen, adding 15% glycerol to prevent protein damage, and
stored at −80∘C.
2.5. Statistical Analysis. Quantitative data are presented as
mean + SEM. All data were statistically analyzed using 𝑡-test
or one-way analysis of variance and post-hoc analysis by the
Bonferroni test (SPSS software).
3. Results
3.1. Comparative Characterization of Primary Glial Cell
Cultures and Glial Cell Lines
3.1.1. Cellular Differentiation of OEC and NOBEC upon GDNF
Treatment under Different Growth Conditions. To character-
ize these cell models in vitro, a stimulation assay was carried
out with Glial cell-derived neurotrophic factor (GDNF), a
well-recognized growth factor for glial cells [23], to both
primary OEC and NOBEC cell line cultures in order to
evaluate its effect on cell survival and expression of glial
differentiation markers. Concentration and exposure time of
the cultures to the GDNF were previously established [24].
In the presence of serum, the majority of OEC and NOBEC
exhibited both star and spindle shapes which are their in vitro
typical morphological features (Figure 1).
Results show a different intensity level in the expres-
sion of some glial markers both in OEC and in NOBEC,
grown in different conditions and treated with GDNF; S-
100 immunoreactivity was higher in OEC and NOBEC
grown in the presence of serum in comparison with cells
grown in serum free medium (SFM); when GDNF was
added to cultures in the presence of serum, an increased
number of positive S-100 both in OEC and in NOBEC was
observed.
Nestin immunoreactivity showed a more intense expres-
sion in NOBEC compared with OEC in all culture conditions
and the addition of GDNF determined an upregulation of
nestin both in serum and in SFM in NOBEC and OEC.
Vimentin was more expressed in OEC grown in the presence
of serum and GDNF addition increased the expression of
vimentin in OEC grown both in serum and in SFM. NOBEC
showed a major expression of vimentin compared with OEC,
especially when they were grown with GDNF both in serum
and in SFM (Figure 1). This different expression suggests that
NOBEC cell line is more resistant to stress thanOEC primary
cultures and that NOBEC might represent a good glial cell
model for in vitro assays.
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Figure 1: OEC andNOBEC respond similarly to GDNF stimulation. Figure shows representative fields of OEC andNOBEC immuno-stained
with anti-S-100, antinestin, and antivimentin antibodies. Cells were grown for eight days after plating with and without serum and GDNF.
Fields were chosen to clearly to show both the morphological aspect and the specific marker expression. Scale bars 50 𝜇m.
3.1.2. Expression Analysis of NRG1/ErbB System and Glial
Markers. ThemRNA expression level of the NRG1/ErbB sys-
tem (Figure 2) and of glial markers (Figure 3) was examined
by quantitative real-timePCR (qRT-PCR) in primary cultures
of Schwann cells (SC) and olfactory bulb ensheathing cells
(OEC) and was compared with the corresponding stable
cell lines RT4-D6P2T (derived from a Schwannoma) and
NOBEC (neonatal olfactory bulb ensheathing cells).
For each gene, the normalized relative quantity (NRQ)
was determined using the sample with the highest level of
expression as calibrator (NRQ= 1); therefore, the relative (and
not absolute) gene expression shown in the graphs cannot be
compared among different genes. Results show that ErbB1 is
expressed by OEC and NOBEC, while SC and RT4-D6P2T
do not express this receptor; ErbB2 is expressed by all cell
types; ErbB3 is expressed by SC and RT4-D6P2T cells, barely
detectable in OEC and NOBEC; ErbB4 mRNA is barely
detectable only in SC and OEC.
To investigate the presence of mRNA coding for NRG1,
different primer pairs were used that allow the amplification
of different NRG1 isoforms [25]. Results show that RT4-
D6P2T cells do not express any NRG1 isoform, whereas OEC
and NOBEC express different NRG1 isoforms (type I/II, 𝛼
and 𝛽, type III); SC express only NRG1 type I/II isoforms
(Figure 2). The glial gene GFAP is expressed by SC, OEC,
and RT4-D6P2T; S100 and p75 are expressed by all cell types,
mostly by SC and RT4-D6P2T (Figure 3).
Immunoblot analysis was performed to confirm protein
expression of some of the genes analyzed by qRT-PCR
(Figure 4). A faint band corresponding to ErbB1 protein is
visible in OEC and NOBEC samples; ErbB2 is expressed, at
different levels, in all samples; ErbB3 is strongly expressed by
SC and RT4-D6P2T and lowly expressed by NOBEC; ErbB4
is not detectable and for this reason a positive control was
added in the Western Blot.
Different NRG1 isoforms are detectable in OEC, NOBEC,
and SC. RT4-D6P2T cell line does not express NRG1.
3.2. Ecto-ErbB4 Stimulates NOBEC Migration. It has been
shown that SC migrate following stimulation with solu-
ble NRG1 and that the removal of soluble NRG1 with
recombinant soluble receptors, such as the soluble extra-
cellular fragment of ErbB3, strongly reduces SC migration
[26].
NOBEC are characterized by highmigratory activity [27],
which could be due to an autocrine stimulation mediated
by endogenous soluble NRG1 on endogenous ErbB3-ErbB2
heterodimer.
To verify this hypothesis, a construct to express the
soluble extracellular domain of ErbB4 (ecto-ErbB4) tagged
with a FLAG was produced (see Materials and Methods).
ByWestern blot analysis the expression of ecto-ErbB4-FLAG
was assayed both in the cell extract and in the supernatant of
transiently transfected COS7 cells, to verify that the soluble
extracellular domain of ErbB4 was expressed and released in
the extracellular environment (Figure 5(a)).
A coimmunoprecipitation assay was performed to verify
the ability of ecto-ErbB4-FLAG to interact with soluble
NRG1: different amounts of soluble recombinant NRG1𝛽1
tagged with 6 histidine [13] were incubated with condi-
tioned medium containing recombinant ecto-ErbB4 tagged
with FLAG. A coimmunoprecipitation against FLAG (ecto-
ErbB4) was performed and coimmunoprecipitated proteins
were analyzed byWestern blot using an antibody against his-
tidine (NRG1𝛽1). Data confirm that ecto-ErbB4 and NRG1𝛽1
interact (Figure 5(b)).
A three-dimensional migration assay (transwell assay)
was performed using NOBEC transiently transfected with
the expression vector for ecto-ErbB4-FLAG (Figure 6(a)).
Contrary to what expected, Transwell assays showed that
the expression of the soluble extracellular portion of
the receptor ErbB4 increased cell migration. The same
results were obtained when NOBEC were transiently trans-
fected with an expression vector for ecto-ErbB3-FLAG
(Figure 6(b)).
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Figure 2: Primary cultures and cell lines derived from OEC and SC express different levels of NRG1 isoforms and ErbB receptors. Graphs
show normalized relative quantification (NRQ) of the different NRG1 isoforms and ErbB receptors obtained by qRT-PCR. For each gene, the
cells with the highest level of expression were chosen as calibrator (NRQ = 1). Data are presented as mean + SEM.
3.3. Ecto-ErbB4-NRG1 Interaction. Thepromigratory activity
elicited by ecto-ErbB4 could be explained by two different
models.
(1) ecto-ErbB4, sequestering endogenous soluble NRG1,
stimulates migration. This hypothesis would be
confirmed if soluble NRG1 would have an inhibitory
effect on NOBEC migration. To test this hypothesis
a Transwell assay was performed in the presence of
50 ng/mL soluble recombinant NRG1𝛽1. Transwell
assay analysis demonstrates that NRG1𝛽1 does not
inhibit migration and, indeed, it slightly stimulates
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quantification (NRQ) of GFAP, S100, and p75 obtained by qRT-PCR. For each gene, the cells with the highest level of expression were chosen
as calibrator (NRQ = 1). Data are presented as mean + SEM.
migration (Figure 6(c)). Therefore, the first model
does not explain the ecto-ErbB4 mediated migration.
(2) ecto-ErbB4, interacting with transmembrane NRG1,
stimulates migration. Actually, it is known that trans-
membrane NRG1 type III isoforms are able to medi-
ate reverse signaling [9, 10]: upon interaction with
ErbB receptor, transmembrane NRG1 undergoes a
proteolytic cleavage mediated by a 𝛾-secretase, which
releases a cytoplasmic fragment which is able to
translocate into the nucleus,mediating reverse signal-
ing.
To verify the expression of NRG1 type III isoforms, an
RT-PCR was carried out using specific primers that amplify
these isoforms on RNA extracted by NOBEC wild type
and NOBEC expressing ecto-ErbB4. RT-PCR confirmed that
these NRG1 isoforms are expressed by NOBEC (data not
shown), both wild type and expressing ecto-ErbB4.
To validate the reverse-signaling hypothesis, a Transwell
migration assay was performed by treating NOBEC express-
ing ecto-ErbB4 and wild type (WT) NOBEC with DAPT, a
specific inhibitor of 𝛾-secretase, the enzyme which mediates
NRG1 proteolytic cleavage, releasing a cytoplasmic fragment.
In both cell lines, treatment with DAPT inhibits the
migration in a consistent way. However, the migration is
inhibited more strongly in NOBEC expressing ecto-ErbB4,
supporting the hypothesis that this soluble fragment, binding
to NRG1-typeIII, leads to the production of a cytoplas-
mic fragment responsible of the stimulus for migration.
The migration is inhibited by 75% in NOBEC expressing
ecto-ErbB4 (Figure 6(e)), while only by 25% in wild type
NOBEC (Figure 6(d)). Actually, there are numerous signaling
pathways that require the presence of 𝛾-secretase for the
propagation of the signal; therefore, treatment with DAPT
could interfere also with the signaling produced by other
signal transduction pathways.
3.4. NRG1 Cytoplasmic Fragment Stimulates NOBEC Migra-
tion. To investigate the role of the cytoplasmic fragment
of NRG1 produced after interaction with ErbB receptors,
two different constructs were prepared to express the NRG1
intracellular domain (ICD): NRG1-ICD-NLS, containing the
nuclear localization sequence (NLS), and NRG1-ICD-ΔNLS,
missing NLS (Figure 7(a)). NLS is a sequence consisting of
eight amino acids (KTKKQRKK) following the transmem-
brane portion of the protein, present in all NRG1 isoforms
containing an ICD [9].
Specific primers were designed with the insertion of an
artificial ATG to allow the expression of the protein in trans-
fected cells; in one primer the nuclear localization sequence
was included; in the other one it was omitted. To verify that
the nuclear localization sequence (NLS) inserted into the
construct NRG1-ICD-NLS works properly, a Western blot
analysis of nuclear and cytoplasmic proteins was performed
(Figure 7(b)).
Western blot data show that cells transfected with the
construct NRG1-ICD-NLS express the protein both in the
cytoplasm and in the nucleus, while cells transfected with
the construct NRG1-ICD-ΔNLS, lacking the nuclear local-
ization sequence, express the protein predominantly in the
cytoplasm. A barely detectable signal can be observed also in
the nucleus; this could be due to the fact that this fragment
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with 100𝜇M DAPT (𝛾-secretase inhibitor) or DMSO (mock control). Cell migration was assessed by Transwell assays. Values represent the
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Figure 7: The expression of NRG1 intracellular domain stimulates cell migration. (a) To express the NRG1 intracellular domain (ICD),
two constructs were prepared: one containing the nuclear localization sequence (NLS) and one lacking it (ΔNLS). ICD is shown in blue,
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interacts with proteins, such as LIMK1 [28], able to enter the
nucleus carrying associated proteins.
Transwell migration assays were performed with wild
type NOBEC transiently transfected with NRG1-ICD-NLS
and NRG1-ICD-ΔNLS (Figure 7(c)).
Migration assay analysis shows that transient expression
of the NRG1 cytoplasmic domain able to translocate into
the nucleus confers a migratory activity that is significantly
higher compared to control cells. Unexpectedly, the expres-
sion of the NRG1 cytoplasmic fragment lacking NLS confers
to the cells a migratory activity that is significantly higher
than control and of the cells expressing the isoform with
NLS. These data suggest that NRG1-ICD plays a role in
the stimulation of the migratory activity, when it is in the
cytoplasm.
3.5. NRG1 Cytoplasmic Fragment Does Not Stimulate RT4-
D6P2T Migration. To understand if the cytoplasmic frag-
ment of NRG1 type III is able to confer migratory activity to
cells that do not express endogenously any isoform of NRG1,
the cell line RT4-D6P2T was transiently transfected with
vectors to express NRG1-ICD-NLS and NRG1-ICD-ΔNLS
and migratory activity was analyzed by Transwell assays
(Figure 7(d)).
Data show that transient expression of NRG1-ICD does
not confer migration activity, suggesting that these cells lack
pivotal factors necessary to mediate NRG1 migratory signal
transduction.
3.6. Signal Transduction Pathways Activated by Ecto-ErbB4 on
the NOBEC Cell Line. It has been shown that in neurons,
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Figure 8: Following lentivirus (LV) infection, RT4-D6P2T successfully express GFP and ecto-ErbB4-FLAG. Confluent cells infected with
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the positive fractions to be frozen and used for the following experiments.
expressing transmembrane NRG1-typeIII, stimulation with
soluble ErbB4 fragment produces an increase in AKT phos-
phorylation, while ERK phosphorylation remains unchanged
[29].
To further investigate the reverse signaling mediated by
ecto-ErbB4 in NOBEC cells, a time course of stimulation was
performed.
To obtain pure and highly concentrated recombinant
protein to stimulate cells, RT4-D6P2T were transduced
with a lentivirus expressing ecto-ErbB4-FLAG (Figure 8).
Conditioned medium was collected from RT4-D6P2T-ecto-
ErbB4-FLAG cells to purify ecto-ErbB4-FLAG through a
chromatographic column (Figure 8(j)). NOBEC cells were
starved 24 h in serum-free medium and then stimulated with
the purified recombinant protein for 5, 10, 15, 30, and 60min.
By Western blot analysis AKT and ERK 1/2 phosphorylation
was analyzed (Figure 9). Data analysis shows that in this glial
cell model, contrary to neuron cells, AKT phosphorylation
does not change, while ERK phosphorylation changes. In
particular, there is a strong increase in ERK2 phosphoryla-
tion and there is a low increase in ERK1 phosphorylation
(Figure 9(c)).
4. Discussion
The study of peripheral nerve repair and regeneration is an
emerging issue in biomedicine since, although peripheral
nerves retain a significant capacity for spontaneous regener-
ation after lesion, regeneration is almost never complete [30]
and functional recovery is often unsatisfactory [31].
Innovative strategies to improve peripheral nerve regen-
eration are expected to arise from the manipulation of the
several trophic factor loops playing a role in this process.
Among them the neuregulin1/ErbB system is attractingmuch
attention because of its action on SC [3, 4]. The aim of this
study was to further explore the role of the neuregulin1/ErbB
system and the potential of its manipulation.
4.1. Neuregulin1 Isoforms and ErbB Receptors Are Differ-
entially Expressed in SC and OEC (Both Primary Cultures
and Cell Lines). The NRG1/ErbB system is involved in the
development of the central and peripheral nervous system,
in which different members of the ErbB receptor family
and different NRG1 isoforms control processes are opposed
to each other, such as proliferation and cell death [32].
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NRG1/ErbB signaling plays a fundamental role in SC pre-
cursor growth and in interactions between SC (expressing
ErbB2-ErbB3 and soluble type I/II NRG1) and axons (mainly
expressing transmembrane NRG1-type III). NRG1-type III
plays an instructive role onmyelination and SC development,
determining the ensheathment fate of axons: its reduced
expression causes hypomyelination [33]. Moreover, NRG1-
type III absence [34] or the lack of coreceptors ErbB3 [35]
or ErbB2 [36, 37] gives rise to mice without or with severely
reduced amount of SC precursors.
In this paper, primary cultures of SC and OEC and
immortalized cultures of SC (RT4-D6P2T) and OEC
(NOBEC), commonly used in in vitro analysis, were
compared and characterized in terms of ErbB receptors,
NRG1 isoforms, P75, S100, and GFAP expression.
Data presented here have shown that RT4-D6P2T cells
are very similar to primary SC, since they express mRNAs for
ErbB2, ErbB3, and the glial genes GFAP, P75, S100, and do not
express mRNA for ErbB1 and NRG1 type III. RT4-D6P2T do
not, however, show detectable expression of NRG1, while SC
express NRG1 type I/II. OEC and NOBEC cell lines express
all NRG1 isoforms; ErbB1 and ErbB2 are expressed in both
OEC and NOBEC, while ErbB3 is slightly expressed. ErbB4
mRNA is barely expressed in OEC and SC, and its protein is
not detectable.
4.2. Ecto-ErbB4 In Vitro Expression Increases NOBEC Migra-
tion. Following the characterization of the four cell popula-
tions as well as the immunohistochemical assay to compare
OEC and NOBEC, we decided to proceed with the study
of NRG1/ErbB system manipulation using the NOBEC line,
which expresses the transcripts for different NRG1 isoforms.
Data previously obtained in our laboratory showed that
NOBEC have a high migratory activity [27]. We speculated
whether the high migration was due to an autocrine loop
induced by self-produced NRG1; in fact, it is known that
glial cells migrate following stimulation with NRG1 [26]. To
negatively interfere with NOBEC migration, we planned to
subtract soluble NRG1 using the recombinant soluble extra-
cellular fragment of ErbB3 or ErbB4 (ecto-ErbB). Contrary
to what expected, results showed that ecto-ErbB3 and ecto-
ErbB4 expression significantly increases cellular migration.
We hypothesized that this migration increase was due to
the interaction between the soluble portion of ErbB4 receptor
and the NRG1 type III expressed by the NOBEC cell line,
through a process of back-signaling that this transmembrane
isoform of NRG1 is able to generate. Usually, this NRG1
isoform is expressed by axons in which the back-signaling
is mediated by the action of a 𝛾-secretase that, following
ligand-receptor interaction, causes the release of a NRG1
cytoplasmic fragment able to translocate into the nucleus
[9], where it can regulate transcription of genes involved in
neuronal development [38].
Actually, we demonstrated that NRG1 intracellular
domain (NRG1-ICD) stimulates migration. Particularly, we
saw that the fragment localized in the cytoplasm, more than
the fragment localized in the nucleus, plays an important
role in the stimulation of the migratory activity. This action
could be due to the interaction between this intracellular
fragment and cytoplasmic binding partners, such as
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the LIMkinase1/LIMK1 [28] that is able to shuttle between the
cytoplasm and the nucleus, by regulating gene transcription
through interaction with the actin cytoskeleton [39].
Interaction between NRG1-ICD and LIMK1 has been found
at the level of synapses, where LIMK1 is involved in the
regulation of the reorganization of actin filaments in the
neuritic protuberances [28, 40, 41].
Transfection of NRG1-ICD in cells that do not express
any isoform of NRG1, like RT4-D6P2T cells line, does not
affectmigration, thus suggesting that these cells lack elements
necessary for the signal transduction mediated by NRG1.
Moreover, we found that stimulation of NOBEC with
the soluble portion of ErbB4 increases ERK phosphorylation
without affecting AKT phosphorylation, contrary to what
happens in neuron cells, in which there is an increase of
AKT phosphorylation [29]; these results suggest that the
back-signaling mediated by NRG1 type III activates signal
transduction pathways which differ according to the cell type.
4.3. Conclusion. This study shows that stable cell lines and the
corresponding primary cultures have many characteristics in
common, thus suggesting that cell lines are a good model
for in vitro studies. On the other hand, these results show
that glial olfactory ensheathing cells and Schwann cells differ
for the expression of some proteins, thus suggesting that the
choice of the cell model for in vitro studiesshould be done
carefully, after investigating the expression of the genes of
interest.
Finally, these results suggest that recombinant ecto-
ErbB4 can be used not only to sequester soluble NRG1,
but also to activate transmembrane NRG1 through a back
signaling pathway that can stimulate cell migration. Thus,
ecto-ErbB4, a protein fragment endogenously released by
cells expressing the cleavable isoform of the NRG1 receptor
ErbB4 [42], turns out to be a potential tool to manipulate
in vivo the neuregulin1/ErbB system. Nevertheless, further
studies are required to design a strategy for a finely tuned
ecto-ErbB4 delivery, to investigate the possibility to promote
posttraumatic peripheral nerve regeneration.
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